FDA Brief

Warning letters Drugs

FDA warning letter to

Elite Supplement Center LLC and Elite Training Facility LLC

High riskIssued Jul 6, 2022Posted Jul 12, 2022Center for Drug Evaluation and Research | CDER

FDA warned Elite Supplement Center that it sells five SARM products as unapproved new drugs for human use.

What happened

FDA reviewed the company's website in June 2022 and found it took orders for five SARM products. The site described the products as muscle builders and fat-loss aids, which FDA said shows they are intended for human use as drugs, even though the labels say "RESEARCH ONLY" and "Not for Human Consumption." No FDA-approved applications are in effect for these products.

What FDA found

  1. The SARM products are new drugs sold without FDA approval, which the law does not allow.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. The products are not generally recognized as safe and effective for the advertised uses, so they count as new drugs.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. Website claims such as muscle gains, fat loss and hormone release show the products are meant for people, despite research-only labels.

  4. Selling these without approval exposes users to serious risks, including liver toxicity and higher risk of heart attack and stroke.

What FDA wants

Within 15 working days, tell FDA in writing what steps you have taken to fix the violations, how you will prevent them from repeating, and include supporting documents. If the work is not done by then, explain why and give a date for completion.

Who should pay attention

  • online retailers selling SARMs labeled 'research only'
  • brands marketing muscle-building or fat-loss claims for unapproved ingredients
  • sports supplement marketers and their compliance reviewers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk